Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Overview of attention for article published in New England Journal of Medicine, March 2018
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (99th percentile)
-
Good Attention Score compared to outputs of the same age and source (75th percentile)
Mentioned by
- news
- 24 news outlets
- blogs
- 2 blogs
- policy
- 2 policy sources
- 153 X users
- patent
- 14 patents
- 1 Facebook page
- wikipedia
- 1 Wikipedia page
- 1 Redditor
- f1000
- 1 research highlight platform
- guideline
- 7 clinical guideline sources
- podcasts
- 1 podcast
Readers on
- mendeley
- 688 Mendeley